10001nightsmegaways| Novavacs Pharmaceuticals fell sharply 5.04% to $4.52 in intraday trading

22:36 on May 07, 2024, Beijing time, Novax Medicine (NVAX)10001nightsmegaways(.us) the stock fluctuated and the stock price plummeted by 5.04%. As of press time, the stock was trading at US $4.52 per share, with a turnover of 1.85328 million shares, a turnover rate of 1.32% and an amplitude of 8.61%.

Lately10001nightsmegawaysThe stock achieved operating income of $984 million, net profit of-$545 million, earnings per share of-$5.41, gross profit of $704 million, and a price-to-earnings ratio of-0.84, according to the company's earnings report.

In terms of institutional ratings, of all the six agencies that participated in the rating, 50 per cent gave buy advice, 17 per cent gave hold advice and 33 per cent gave sell advice.

Novak Pharmaceuticals shares in the biotechnology industry, the overall increase of 0.74%. Among its related stocks, Fa Bojin, Lexaria Bioscience Corp C/Wts 14 Holdings 01max 2026 (To Pur Com), Geovax Labs Inc C/Wts 29max 09 Accord 2025 (To Pur Com) rose significantly, Clearmind Medicine Inc., Tc Biopharm (Holdings) Plc, Allarity Therapeutics10001nightsmegaways, Inc. It is more active, with turnover rates of 1379.60%, 167.20% and 162.47% respectively. The related stocks with larger amplitudes are Clearmind Medicine Inc., Tc Biopharm (Holdings) Plc and Fa Bojin, with amplitudes of 37.61%, 37.16% and 32.76%, respectively.

Brief introduction of Novax Pharmaceutical Co., Ltd.10001nightsmegawaysNovax Pharmaceuticals is a biotech company that develops vaccines. The company is in the stage of clinical development and focuses on providing new products to prevent a variety of diseases. Novavax works with its wholly-owned Swedish subsidiary to produce candidate vaccines to address known and emerging disease threats. The company believes that its vaccine technology is likely to be widely used in a variety of human infectious diseases. The company manages its business as an operational unit, that is, the development and commercialization of vaccines. The company gets the largest revenue from Europe.

(the above content is Portfolio based on public information, intelligently generated by programs or algorithms, only as a reference for users to view the market, not as investment advice or transaction basis. The stock market is risky, please make a careful decision. )